(EHAB) Enhabit - Ratings and Ratios
Home Health, Hospice, Therapy, Chronic Care, Palliative
EPS (Earnings per Share)
Revenue
Dividends
Currently no dividends paid| Risk via 10d forecast | |
|---|---|
| Volatility | 55.1% |
| Value at Risk 5%th | 75.3% |
| Relative Tail Risk | -16.99% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.51 |
| Alpha | 7.42 |
| CAGR/Max DD | -0.23 |
| Character TTM | |
|---|---|
| Hurst Exponent | 0.454 |
| Beta | 0.691 |
| Beta Downside | 0.735 |
| Drawdowns 3y | |
|---|---|
| Max DD | 59.30% |
| Mean DD | 37.24% |
| Median DD | 41.98% |
Description: EHAB Enhabit October 24, 2025
Enhabit, Inc. (NYSE: EHAB) is a Dallas-based provider of home health and hospice services across the United States, offering a broad portfolio that includes skilled nursing, chronic disease management, therapy, and end-of-life care. The company rebranded from Encompass Health Home Health Holdings in March 2022 and has operated since 1998.
Key operational metrics (FY 2023) show revenue of roughly $1.1 billion, with a home-health segment contribution of about 68 % and a hospice contribution of 32 %. The firm reported an adjusted EBITDA margin near 7 %, reflecting the pressure of Medicare-centric reimbursement rates and the need for cost-efficient staffing models. Recent quarterly filings indicate a 4 % YoY increase in patient admissions, driven partly by the aging U.S. population and rising prevalence of chronic conditions such as diabetes and heart failure.
The home-health sector is currently expanding at a compound annual growth rate of 6-7 % (2022-2027), propelled by demographic trends, policy shifts favoring home-based care, and tighter hospital length-of-stay constraints. However, reimbursement uncertainty-particularly potential changes to Medicare’s Home Health Prospective Payment System-introduces upside/downside risk that Enhabit must navigate.
For a deeper quantitative assessment, you may find ValueRay’s analyst toolkit useful for benchmarking Enhabit against peers.
Piotroski VR‑10 (Strict, 0-10) 4.5
| Net Income (-11.9m TTM) > 0 and > 6% of Revenue (6% = 62.9m TTM) |
| FCFTA 0.05 (>2.0%) and ΔFCFTA 0.68pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 7.46% (prev 6.30%; Δ 1.17pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.05 (>3.0%) and CFO 62.2m > Net Income -11.9m (YES >=105%, WARN >=100%) |
| Net Debt (459.6m) to EBITDA (59.2m) ratio: 7.76 <= 3.0 (WARN <= 3.5) |
| Current Ratio 1.58 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (51.1m) change vs 12m ago 1.79% (target <= -2.0% for YES) |
| Gross Margin 48.43% (prev 46.56%; Δ 1.88pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 82.75% (prev 79.52%; Δ 3.22pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 0.93 (EBITDA TTM 59.2m / Interest Expense TTM 36.5m) >= 6 (WARN >= 3) |
Altman Z'' 1.17
| (A) 0.06 = (Total Current Assets 213.7m - Total Current Liabilities 135.5m) / Total Assets 1.23b |
| (B) 0.11 = Retained Earnings (Balance) 132.4m / Total Assets 1.23b |
| (C) 0.03 = EBIT TTM 33.8m / Avg Total Assets 1.27b |
| (D) 0.21 = Book Value of Equity 132.9m / Total Liabilities 631.0m |
| Total Rating: 1.17 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 43.19
| 1. Piotroski 4.50pt |
| 2. FCF Yield 6.49% |
| 3. FCF Margin 5.52% |
| 4. Debt/Equity 0.91 |
| 5. Debt/Ebitda 7.76 |
| 6. ROIC - WACC (= -2.02)% |
| 7. RoE -2.18% |
| 8. Rev. Trend -67.57% |
| 9. EPS Trend -51.60% |
What is the price of EHAB shares?
Over the past week, the price has changed by +11.34%, over one month by +5.24%, over three months by +12.87% and over the past year by +18.50%.
Is EHAB a buy, sell or hold?
- Strong Buy: 1
- Buy: 0
- Hold: 4
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the EHAB price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 9.5 | 5.2% |
| Analysts Target Price | 9.5 | 5.2% |
| ValueRay Target Price | 9.1 | 0.8% |
EHAB Fundamental Data Overview November 25, 2025
P/E Forward = 16.2866
P/S = 0.4112
P/B = 0.7589
Beta = 1.317
Revenue TTM = 1.05b USD
EBIT TTM = 33.8m USD
EBITDA TTM = 59.2m USD
Long Term Debt = 441.5m USD (from longTermDebt, last quarter)
Short Term Debt = 35.2m USD (from shortTermDebt, last quarter)
Debt = 516.5m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 459.6m USD (from netDebt column, last quarter)
Enterprise Value = 890.5m USD (430.9m + Debt 516.5m - CCE 56.9m)
Interest Coverage Ratio = 0.93 (Ebit TTM 33.8m / Interest Expense TTM 36.5m)
FCF Yield = 6.49% (FCF TTM 57.8m / Enterprise Value 890.5m)
FCF Margin = 5.52% (FCF TTM 57.8m / Revenue TTM 1.05b)
Net Margin = -1.14% (Net Income TTM -11.9m / Revenue TTM 1.05b)
Gross Margin = 48.43% ((Revenue TTM 1.05b - Cost of Revenue TTM 540.3m) / Revenue TTM)
Gross Margin QoQ = 48.48% (prev 46.94%)
Tobins Q-Ratio = 0.72 (Enterprise Value 890.5m / Total Assets 1.23b)
Interest Expense / Debt = 1.61% (Interest Expense 8.30m / Debt 516.5m)
Taxrate = 21.62% (3.20m / 14.8m)
NOPAT = 26.5m (EBIT 33.8m * (1 - 21.62%))
Current Ratio = 1.58 (Total Current Assets 213.7m / Total Current Liabilities 135.5m)
Debt / Equity = 0.91 (Debt 516.5m / totalStockholderEquity, last quarter 566.8m)
Debt / EBITDA = 7.76 (Net Debt 459.6m / EBITDA 59.2m)
Debt / FCF = 7.95 (Net Debt 459.6m / FCF TTM 57.8m)
Total Stockholder Equity = 546.5m (last 4 quarters mean from totalStockholderEquity)
RoA = -0.97% (Net Income -11.9m / Total Assets 1.23b)
RoE = -2.18% (Net Income TTM -11.9m / Total Stockholder Equity 546.5m)
RoCE = 3.42% (EBIT 33.8m / Capital Employed (Equity 546.5m + L.T.Debt 441.5m))
RoIC = 2.56% (NOPAT 26.5m / Invested Capital 1.03b)
WACC = 4.58% (E(430.9m)/V(947.4m) * Re(8.56%) + D(516.5m)/V(947.4m) * Rd(1.61%) * (1-Tc(0.22)))
Discount Rate = 8.56% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 1.09%
[DCF Debug] Terminal Value 75.80% ; FCFE base≈55.7m ; Y1≈53.5m ; Y5≈52.5m
Fair Price DCF = 16.81 (DCF Value 850.9m / Shares Outstanding 50.6m; 5y FCF grow -5.17% → 3.0% )
EPS Correlation: -51.60 | EPS CAGR: -29.26% | SUE: 2.01 | # QB: 1
Revenue Correlation: -67.57 | Revenue CAGR: -1.23% | SUE: -0.84 | # QB: 0
Additional Sources for EHAB Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle